Format

Send to

Choose Destination
Thyroid. 2016 Feb;26(2):256-61. doi: 10.1089/thy.2015.0376. Epub 2015 Dec 16.

Bethesda Categorization of Thyroid Nodule Cytology and Prediction of Thyroid Cancer Type and Prognosis.

Author information

1
1 Thyroid Unit, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School , Boston, Massachusetts.
2
2 Department of Endocrinology, First Affiliated Hospital of Nanjing Medical University , Nanjing, China .
3
3 Rotterdam Thyroid Center and Department of Internal Medicine, Erasmus Medical Center , Rotterdam, the Netherlands .
4
4 Department of Surgery, Brigham and Women's Hospital and Harvard Medical School , Boston, Massachusetts.
5
5 Department of Pathology, Brigham and Women's Hospital and Harvard Medical School , Boston, Massachusetts.

Abstract

BACKGROUND:

Since its inception, the Bethesda System for Reporting Thyroid Cytopathology (TBS) has been widely adopted. Each category conveys a risk of malignancy and recommended next steps, though it is unclear if each category also predicts the type and extent of malignancy. If so, this would greatly expand the utility of the TBS by providing prognostic information in addition to baseline cancer risk.

METHODS:

All patients prospectively enrolled into the authors' thyroid nodule database from 1995 to 2013 with histologically proven malignancy were analyzed. The primary ultrasound-guided fine-needle aspiration cytology (AUS, atypia of unknown significance; FN, follicular neoplasm; SUSP, suspicious; M, malignant) was correlated with the type of thyroid cancer and histological features known to impact prognosis and recurrence, including lymph node metastasis (LNM), lymphovascular invasion, and extrathyroidal extension (ETE). Primary cytology was separately correlated with higher risk malignancy.

RESULTS:

A total of 1291 malignancies were identified, with primary cytology AUS in 130 cases, FN in 241 cases, SUSP in 411 cases, and M in 509 cases. AUS, SUSP, and M cytology were progressively associated with an increasing risk of high-risk disease (p < 0.001), LNM (p < 0.001), ETE (p < 0.001), and margin positivity (p < 0.001). Notably, 71% of malignancies with AUS cytology were follicular variants of papillary thyroid cancer compared with 63% with SUSP cytology and only 20% with M cytology. In contrast, high-risk malignancies were diagnosed in only 4% with AUS cytology, but 9% and 27% with SUSP and M cytology, respectively. FN conveyed a significantly increased risk of follicular thyroid carcinoma compared with all other types (28% vs. 2%; p < 0.001). A composite endpoint of recurrence, distant metastases, and death similarly increased as cytology progressed from AUS to SUSP to M (p < 0.001).

CONCLUSION:

In addition to predicting cancer prevalence, the TBS also imparts important prognostic information about cancer type, variant, and risk of recurrence. These data extend the utility of TBS classification by fostering an improved understanding of the risk posed by any confirmed malignancy.

PMID:
26563459
PMCID:
PMC4754507
DOI:
10.1089/thy.2015.0376
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center